Literature DB >> 22264864

Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.

Jp Cramer1, T Mac, B Hogan, S Stauga, S Eberhardt, O Wichmann, T Mertens, Gd Burchard.   

Abstract

The 2009 influenza pandemic has introduced the new re-assorted influenza A(H1N1)pdm09 virus which recirculated during the 2010/11 influenza season. Before that season, it was possible to acquire protective immunity either by pandemic or seasonal influenza vaccination against influenza A(H1N1)pdm09 or by natural infection. To obtain data on vaccination coverage and antibody levels in a reference population and to calculate whether or not the herd immunity threshold (HIT, calculated as 33% given an R0 of 1.5) was reached at the beginning of the 2010/11 season we performed a seroprevalence study in November 2010 in Hamburg, Germany. Antibody titres were assessed applying a haemagglutination inhibition test. Vaccination coverage was very low: 14% for pandemic and 11% for seasonal 2010/11 vaccinations. Even in those with underlying risk factors, vaccination coverage was not much higher: 17% for both vaccines. Serological analysis revealed antibody titres of ≥1:10 in 135 of 352 (38%) and of ≥1:40 in 61 of 352 study participants (17%). Specific antibodies were measurable in 26% of those without history of vaccination or natural infection, indicating a high proportion of subclinical and mild influenza disease. Nevertheless, the HIT was not reached, leaving the majority of the population susceptible to influenza A(H1N1)pdm09 and its potential complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264864

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  10 in total

1.  Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011.

Authors:  Anne Hackenberg; Gökhan Arman-Kalcek; Jens Hiller; Gülsah Gabriel
Journal:  Med Microbiol Immunol       Date:  2012-06-10       Impact factor: 3.402

2.  Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany.

Authors:  Andi Krumbholz; Jeannette Lange; Ralf Dürrwald; Mario Walther; Thomas H Müller; Detlef Kühnel; Peter Wutzler; Andreas Sauerbrei; Roland Zell
Journal:  Med Microbiol Immunol       Date:  2013-09-08       Impact factor: 3.402

3.  A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Authors:  Louise Roggelin; Christof D Vinnemeier; Seetha Meyer; Kai Witte; Lydia Marx; Wiebke Theeß; Gerd D Burchard; Thierry Rolling; Jakob P Cramer
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Authors:  Christof David Vinnemeier; Johanna Fischer-Herr; Seetha Meyer; Katja Liebig; Wiebke Theeß; Gerd-Dieter Burchard; Jakob P Cramer
Journal:  Hum Vaccin Immunother       Date:  2013-11-15       Impact factor: 3.452

5.  Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.

Authors:  Yulia A Desheva; Tatiana A Smolonogina; Svetlana A Donina; Larisa G Rudenko
Journal:  BMC Res Notes       Date:  2015-04-10

6.  2015 Resurgence of Influenza A (H1N1) 09: Smoldering Pandemic in India?

Authors:  Baijayantimala Mishra
Journal:  J Glob Infect Dis       Date:  2015 Apr-Jun

7.  Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia.

Authors:  Jodie McVernon; Karen Laurie; Helen Faddy; David Irving; Terry Nolan; Ian Barr; Anne Kelso
Journal:  Influenza Other Respir Viruses       Date:  2013-12-31       Impact factor: 4.380

8.  Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Authors:  Micha Loebermann; Ulrich Voss; Seetha Meyer; Dietrich Bosse; Carlos Fritzsche; Sebastian Klammt; Silvius Frimmel; Diana Riebold; Emil C Reisinger
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

9.  Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11-2012/13.

Authors:  Andrea Streng; Christiane Prifert; Benedikt Weissbrich; Johannes G Liese
Journal:  BMC Infect Dis       Date:  2015-12-18       Impact factor: 3.090

10.  Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis.

Authors:  Vikramraj K Jain; Nandhini Bhashini; L Karthik Balajee; Sujatha Sistla; Subhash Chandra Parija; Vir Singh Negi
Journal:  Indian J Med Res       Date:  2017-04       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.